The FDA approves Ionis' Zanvastro as the first treatment for Alexander disease, clearing the way for the company's first solo neurology launch.
September 4, 2026 10:46 AM EDT
Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval
Ionis Pharmaceuticals got FDA approval of its rare neurodegenerative disease treatment zilganersen, paving the way for the company’s first wholly owned …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
Rare Brain Disorder Gets Its First FDA Drug Approval
FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive…
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,”…
Zilganersen targets protein buildup that drives Alexander disease
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing deal for zilganersen
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first…
